Shandong Weigao Group (SHWGF) Fair Value & Analysis
Healthcare · US · Market cap $1.9B
Shandong Weigao Group
SHWGF · US
Fair value as of: Jul 21, 2026
From 26 valuation models · updated 2 days ago
Fair value updated Jul 21, 2026, revised from $1.45 to $1.15 (−20.7%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.3346 – $2.03 · fair‑value band $0.8600 – $1.44 · the $0.4300 price screens below the $1.15 fair value. As of Jul 21, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Shandong Weigao Group (SHWGF) currently trades at $0.4300, while our model-based Fair Value estimate is $1.15, implying the stock looks roughly 167.4% undervalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Shandong Weigao Group generated revenue of $13.4B at a net margin of 12.0%. Revenue grew 4.5% year over year. It earns a return on equity of 6.7%. The balance sheet holds a net cash position of $3.9B. Fundamentals as of Jul 21, 2026
Our scenario range runs from $0.8600 (bear case) to $1.44 (bull case); at $0.4300, the current price sits below that range. The share trades about 41% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside, at 167%, SHWGF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 21, 2026. TTM = trailing twelve months.
About the company
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, wholesale, and sale of medical devices in the People's Republic of China and internationally. It operates through Medical Device Products, Orthopedic Products, Pharma Packaging Products, Interventional Products, Blood Management Products, and Others segments. The company offers medical device products, including safe infusion, clinical nursing, perioperative, endocrine, urinary, rehabilitation system, and extracorporeal circulation solutions; pharma packaging products comprising prefilled drug delivery system, pharmaceutical packaging consumables, and automatic drug delivery systems; and orthopedic products that include spine, joint, trauma, sports medicine, bone repair material, and spinal endoscope products, as well as orthopedic devices, PRP treatment consumables, and negative pressure drainage consumables. It also provides interventional products, such as tumor, vascular, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shandong Weigao Group reported revenue of $13.0B in FY2025 versus $13.2B in FY2021, a compound −0.2%/yr. Reported net income was $1.6B in FY2025, compounding −8.9%/yr from FY2021.
Is SHWGF fairly valued? → Check now
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | C$20.93 | C$6.03 | -71% |
| EssilorLuxottica Société anonyme ESLOF | $192.00 | $126.51 | -34% |
| Medline Inc MDLN | $33.61 | $31.78 | -5% |
| HOYA Corporation HOCPY | $178.46 | $103.27 | -42% |
| Becton, Dickinson and Company BDX | $140.71 | $104.17 | -26% |
| Alcon Inc ALC | $66.58 | $36.99 | -44% |
| ResMed Inc RMD | $191.26 | $187.89 | -2% |
| West Pharmaceutical Services, Inc WST | $329.71 | $137.28 | -58% |
| Terumo Corporation TRUMF | $12.89 | $12.65 | -2% |
| Straumann Holding SAUHY | $12.16 | $5.50 | -55% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shandong Weigao Group (SHWGF) undervalued?
What is the fair value of SHWGF?
What is the quality score of SHWGF?
What is the revenue of Shandong Weigao Group (SHWGF)?
What is the net profit margin of SHWGF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Shandong Weigao Group analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.